Patent · US Active

CYBP as a marker for lung cancer

US8951738B2 · kind B2 · utility

0Cited by

0References

14Claims

0Family size

Assignee

Roche Diagnostics Operations, Inc. · US

Inventors

Herbert Andres · Penzberg, DE
Johann Karl · Peißenberg, DE
Julia Riedlinger · Ottobrunn, DE
Markus Roessler · Germering, DE
Michael Tacke · Munich, DE
Michael Thierolf · Schlehdorf, DE

Key dates

Filing date	Oct 11, 2011
Grant date	Feb 10, 2015
Priority date	—
Expiry date	Jun 23, 2032

Classification

Technology area (CPC G)Physics
CPC primaryG01N2333/4727
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

The present invention relates to the assessment of lung cancer. It discloses the use of protein CYBP in the assessment of lung cancer. It also relates to a method for assessing lung cancer in vitro using a liquid sample, derived from an individual by measuring CYBP in said sample. Measurement of CYBP can, e.g., be used in the early detection or in the follow-up of patients with lung cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.